Xenon Pharmaceuticals Inc (XENE) is a publicly traded Healthcare sector company. As of May 20, 2026, XENE trades at $54.67 with a market cap of $5.19B and a P/E ratio of -12.52. XENE moved +1.17% today. Year to date, XENE is +30.84%; over the trailing twelve months it is +73.97%. Its 52-week range spans $26.74 to $63.95. Analyst consensus is strong buy with an average price target of $78.37. Rallies surfaces XENE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Xenon Secures $1.3B Cash Runway, Eyes Q3 2026 NDA After 53.2% Seizure Reduction: Xenon’s Phase 3 X-TOLE2 study achieved a 53.2% median reduction in focal seizure frequency at 25mg versus 10.4% placebo, enabling NDA submission in Q3 2026. The company holds $1.3B cash into 2029 and advances other Phase 3 epilepsy and depression studies along with Phase 1 pain candidates.
| Metric | Value |
|---|---|
| Price | $54.67 |
| Market Cap | $5.19B |
| P/E Ratio | -12.52 |
| EPS | $-4.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $63.95 |
| 52-Week Low | $26.74 |
| Volume | 860.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.50M |
| Net Income | $-345.91M |
| Gross Margin | 0.00% |
19 analysts cover XENE: 0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $78.37.